Caudatin， a C-21 steroidal glyco-side isolated from Chinese herbs， has a long history of use for the treatment of multiple diseases， including cancers. However， the precise mechanisms of actions of caudatin in human uterine cancer cells remain unclear. In this study， we investigated the molecular mechanisms by which caudatin inhibits cell growth in human cervical carcinoma cell line (HeLa) and endometrial carcinoma cell line (HEC-1A). Treatment with caudatin promoted cell morphology change， inhibited cell proliferation， colony formation， migration and spheroid formation， and induced cell apoptosis. Our results showed that the expression of tumor necrosis factor; α-induced protein 1 (TNFAIP1) was downregulated in uterine cancer cells and tissues compared to paired adjacent non-tumor uterine tissues. Further molecular mechanism study showed that caudatin can directly regulate TNFAIP1 expression in a concentration-dependent manner and also associated with the downregulation of NF-κB and upregulation of BAXcL-2 ratio and caspase-3. Moreover， we found that overexpression of TNFAIP1 inhibits the growth and invasion， and induces apoptosis in uterine cancer cells through inhibition of the NF-κB pathway， suggesting that TNFAIP1 may act as a potential therapeutic target for the treatment of cancer. We found that caudatin inhibited tumorigenicity and upregulated TNFAIP1 in vivo. Taken together， caudatin impacts on cell proliferation， migration and apoptosis of uterine cancer cells by regulating several carcinogenesis-related processes， including a novel mechanism involving the targeting of TNFAIP1/NF-κB signaling. Our findings provide new insights into understanding the anticancer mechanisms of caudatin in human uterine cancer therapy.